Receive a copy of our current research models and services product guide.
Target Sufficiency® enables direct, quantitative analysis of drug target systems in cells, biofluids, tissues, and tissue models, including formalin-fixed, paraffin-embedded (FFPE) tissues.
Reduce costs with our complimentary sample for evaluation in your lab.
Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
May 2-3, 2024 West Lafayette, IN The mission of the GLDMDG is to facilitate interactions among scientists from industry and academia interested in all aspects of drug metabolism...
May 6-10, 2024 San Antonio, TX Booth #45 Each year WRIB provides you with novel case studies and emerging scientific approaches. It is the only progra...
May 15, 2024 Wednesday, May 15, from 11 am–12 pm EDT Hosted Online Managing a research project requires close attention to not only the type of animal model but ...
April 29, 2024 WEST LAFAYETTE, IN - April 29, 2024 -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract resea...
February 07, 2024 – First quarter fiscal 2024 revenue up 10.3% to $135.5 mi...
January 29, 2024 WEST LAFAYETTE, Ind., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a lea...
How Differences Between Experimental IBD Models Can Impact Your Drug Development Program
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
Copyright © 2024 Inotiv. All Rights Reserved.